These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34993941)

  • 21. Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.
    Zheng C; Fass JN; Shih YP; Gunderson AJ; Sanjuan Silva N; Huang H; Bernard BM; Rajamanickam V; Slagel J; Bifulco CB; Piening B; Newell PHA; Hansen PD; Tran E
    Cancer Cell; 2022 Apr; 40(4):410-423.e7. PubMed ID: 35413272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
    Vilimas T
    Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.
    Lau TTY; Sefid Dashti ZJ; Titmuss E; Pender A; Topham JT; Bridgers J; Loree JM; Feng X; Pleasance ED; Renouf DJ; Schrader KA; Sun S; Ho C; Marra MA; Laskin J; Karsan A
    J Mol Diagn; 2022 Jun; 24(6):609-618. PubMed ID: 35367630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving neoantigen profiles in colorectal cancers with DNA repair defects.
    Rospo G; Lorenzato A; Amirouchene-Angelozzi N; Magrì A; Cancelliere C; Corti G; Negrino C; Amodio V; Montone M; Bartolini A; Barault L; Novara L; Isella C; Medico E; Bertotti A; Trusolino L; Germano G; Di Nicolantonio F; Bardelli A
    Genome Med; 2019 Jun; 11(1):42. PubMed ID: 31253177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational Prediction and Validation of Tumor-Associated Neoantigens.
    Roudko V; Greenbaum B; Bhardwaj N
    Front Immunol; 2020; 11():27. PubMed ID: 32117226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and clinical development of neoantigen vaccines.
    Li L; Goedegebuure SP; Gillanders WE
    Ann Oncol; 2017 Dec; 28(suppl_12):xii11-xii17. PubMed ID: 29253113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
    de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
    Front Immunol; 2021; 12():592031. PubMed ID: 34335558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolutionary dynamics of neoantigens in growing tumors.
    Lakatos E; Williams MJ; Schenck RO; Cross WCH; Househam J; Zapata L; Werner B; Gatenbee C; Robertson-Tessi M; Barnes CP; Anderson ARA; Sottoriva A; Graham TA
    Nat Genet; 2020 Oct; 52(10):1057-1066. PubMed ID: 32929288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
    McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
    Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma.
    Perumal D; Imai N; Laganà A; Finnigan J; Melnekoff D; Leshchenko VV; Solovyov A; Madduri D; Chari A; Cho HJ; Dudley JT; Brody JD; Jagannath S; Greenbaum B; Gnjatic S; Bhardwaj N; Parekh S
    Clin Cancer Res; 2020 Jan; 26(2):450-464. PubMed ID: 31857430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
    De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
    Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Best practices for bioinformatic characterization of neoantigens for clinical utility.
    Richters MM; Xia H; Campbell KM; Gillanders WE; Griffith OL; Griffith M
    Genome Med; 2019 Aug; 11(1):56. PubMed ID: 31462330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer.
    Yang H; Yu M; Zhong S; You Y; Feng F
    J Ovarian Res; 2022 Jan; 15(1):18. PubMed ID: 35093146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
    Litchfield K; Reading JL; Puttick C; Thakkar K; Abbosh C; Bentham R; Watkins TBK; Rosenthal R; Biswas D; Rowan A; Lim E; Al Bakir M; Turati V; Guerra-Assunção JA; Conde L; Furness AJS; Saini SK; Hadrup SR; Herrero J; Lee SH; Van Loo P; Enver T; Larkin J; Hellmann MD; Turajlic S; Quezada SA; McGranahan N; Swanton C
    Cell; 2021 Feb; 184(3):596-614.e14. PubMed ID: 33508232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.